[et_pb_section fb_built=”1″ admin_label=”! !! NE PAS MODIFIER ! !! ” _builder_version=”4.19.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_row admin_label=”!!! PLEASE DO NOT EDIT !!! ” _builder_version=”4.19.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.19.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”TO BE EDITED – SUMMARY ” _builder_version=”4.21.0″ _module_preset=”default” custom_padding=”||20px||false|false” global_colors_info=”{}”]<\/p>\n
In 2023, French health insurance reimbursed \u20ac25.5 billion worth of drugs, or 12% of total expenditure. The increase was driven by innovative treatments and hospital prescriptions. Generics and biosimilars are key to controlling costs. <\/strong><\/p>\n [\/et_pb_text][et_pb_text admin_label=”TO BE EDITED – TEXT OF THE NEWS – BLOCK 1″ _builder_version=”4.21.0″ _module_preset=”default” custom_padding=”||1em||false|false” global_colors_info=”{}”]In a press kit published on November 14, 2024, the French health insurance system presents an overview of drug expenditure in France for the year 2023. Drug reimbursements reached \u20ac25.5 billion, representing 12% of total Health Insurance expenditure. Since 2021, this sum has grown at an average annual rate of 3.4%. Among drugs dispensed in towns and cities, 45% of expenditure is linked to prescriptions by doctors practicing in hospitals (versus 32% in 2017).[\/et_pb_text][et_pb_text admin_label=”TO BE EDITED – TEXT OF THE NEWS – BLOCK 1″ _builder_version=”4.21.0″ _module_preset=”default” custom_padding=”||1em||false|false” global_colors_info=”{}”]<\/p>\n In 2023, the most-reimbursed drugs include innovative treatments, reflecting a trend towards prescribing newer, more expensive products. The 20 most-reimbursed drugs alone total \u20ac7.3 billion, with an average reimbursement rate of almost 96%. This dynamic trend is fuelled by an increase in prescriptions for serious or chronic pathologies (ALD), often covered at 100% by the French health insurance system. <\/p>\n [\/et_pb_text][et_pb_text admin_label=”TO BE EDITED – TEXT OF THE NEWS – BLOCK 2 ” _builder_version=”4.21.0″ _module_preset=”default” custom_padding=”||1.5em||false|false” global_colors_info=”{}”]<\/p>\n Finally, the dossier highlights the importance of generic and biosimilar drugs in controlling health insurance expenditure. An awareness-raising campaign has also been launched to encourage the appropriate use of medicines. The continuing rise in reimbursement rates, reaching almost 91%, demonstrates, according to the Assurance Maladie, a strong commitment to access to care, while at the same time controlling the costs associated with therapeutic innovation. <\/p>\n [\/et_pb_text][et_pb_text admin_label=”TO BE EDITED – TEXT OF THE NEWS – BLOCK 3″ _builder_version=”4.21.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n Find out more<\/strong><\/p>\n